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Abstract 
There is growing demand for simple to operate, sensitive, on-site quantitative assays to 
investigate concentrations of drug molecules in pharmaceutical preparations for quality 
assurance. Here, we report on the development of two colorimetric analysis methods for 
the study the antibiotic doxycycline hyclate (DOX) and the nasal decongestant 
oxymetazoline hydrochloride (OXY), in solution as well as in their respective formulations. 
We compare a UV/vis spectrophotometry method with a color change recorded on a 
microfluidic paper-based analytical device (µPAD). Detection is based on the 
pharmaceutical compounds coupling with diazotized 4-aminoacetophenone (DAAP) 
under alkaline conditions to produce colored azo-dye products. These azo compounds 
were monitored by absorbance at 425 nm for DOX and 521 nm for OXY, with linear 
calibration graphs in the concentration range of 0.5–35 mg L-1 (DOX) and 1.0–40 mg L-1 
(OXY) and limits of detection of 0.24 mg L-1 (DOX) and 0.32 mg L-1 (OXY). For the µPAD 
method, color intensity was measured from photographs and a linear increase was 
observed at concentrations from above approximately 15 mg L-1 for both compounds and 
up to 35 mg L-1 for DOX and 40 mg L-1 for OXY. The developed methods were also applied 
to the formulated pharmaceuticals and no interference was found from the excipient. 
Thus, the paper-based device provides an inexpensive, simple alternative approach for 
use outside centralized laboratories with semi-quantitative capability. 
Keywords: Doxycycline hyclate, oxymetazoline hydrochloride, spectrophotometry, microfluidic 
paper-based analytical device (µPADs), pharmaceutical formulations. 





Production and distribution of quality controlled pharmaceuticals is vital to the treatment 
and prevention of diseases across the globe. The analysis of active pharmaceutical 
ingredients (APIs) is considered as a key part of this process1, 2. Hence, there is a need for 
the development of rapid and deployable analytical techniques for clinical monitoring and 
industrial quality control to address the current lack of routine monitoring and poor 
regulation within the pharmaceutical industry of developing countries such as Iraq3-5. 
Here, we aim to address these challenges by studying two different pharmaceuticals, 
namely (i) a broad spectrum antibiotic, doxycycline hyclate (DOX), and (ii) oxymetazoline 
hydrochloride (OXY), an adrenergic drug used in eye and nose drops. 
 
Doxycycline hyclate is derived from oxytetracycline or metacycline6, with activity against 
a wide range of gram-positive and gram-negative organisms.7 It is commonly prescribed 
in case of respiratory, skin and soft tissue infection as well as the treatment of sexually 
transmitted infections8 and is also employed to treat infection in veterinary medicine.9 
Various methods for the determination of DOX concentration in vitro and in vivo have 
been reported10-15 (table S1). Typically traditional laboratory-based techniques, such as 
high performance liquid chromatograph (HPLC) with spectroscopy detection are 
employed, which have the potential to achieve sub-mg L-1 sensitivity. For the 
determination of DOX concentration in pharmaceutical tablets, an HPLC method with 
UV/vis absorbance detection was developed achieving a limit of detection (LOD) and limit 
of quantification (LOQ) of 2.8 and 8.6 mg L-1, respectively.16 Spectroscopic methods have 
also been developed such as using UV/vis absorbance detection of the compound in HCl 
and NaOH solutions, achieving sensitivities of 0.3 and 0.2 mg L-1, respectively.15 In a 
further reported spectroscopic method, DOX was reacted with sodium nitrite and 
benzocaine in an alkaline medium to produce a yellow -orange azo-dye complex, 




Oxymetazoline hydrochloride (OXY), is an imidazoline derivative often used as a 
decongestant. It is a non-selective adrenergic drug and used in eye and nose drops.18 
Several analytical techniques have been used for the determination of OXY 
concentration19  (table S2). High performance liquid chromatography20 is typically 
favored, achieving low sensitivity with LODs of sub mg L-1.21 Flow injection have also been 
investigated. Since oxymetazoline hydrochloride inhibits the luminol–permanganate 
reaction under certain conditions, a chemiluminescent flow injection analysis system was 
developed with an LOD of 1.2 µg L-1. 22 
 
Many of the previously mentioned techniques require sophisticated instruments, 
expensive reagents, involve several manipulation steps and derivatization reactions. 
Colorimetric techniques are an attractive alternative and are preferred for routine 
analytical work for pharmaceutical preparation analysis 23-26 due to their simplicity and 
reasonable sensitivity (mg L-1 range), along with significant economic advantages.27, 28  
As both compounds, DOX and OXY, have similar chemical structures featuring phenolic 
groups, they can be reacted with sodium nitrite and a diazonium ion to form brightly 
colored azo dyes that can be monitored by UV/vis spectroscopy.  
 
Paper-based analytical platforms have recently emerged as an attractive measurement 
substrate for point-of-need analysis. 29, 30 Typically cellulose filter paper is used, this is low 
cost and lightweight and can be easily patterned with hydrophobic wax barriers using 
standard solid wax ink printers31, 32 to create channels and reaction zones within the paper 
matrix. Fluid is transported into and through the paper by capillary forces, and where 
needed reagents can be stored in the porous network.33, 34 Due to these properties 
microfluidic paper-based analytical devices (μPADs) have been developed for a variety of 
applications including health diagnostics 35-40, environmental monitoring 41-45, as well as 
food quality testing.40, 46-49 Many paper-based devices rely on colorimetric assays as a 
readout with results gauged by eye or captured by a cell phone camera or scanner and 
color intensity quantified by computer-based image analysis software. 50-52 Quantification 
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of color intensity is supported by comparison of intensities produced by a known standard 
solution to an unknown. The paper microfluidic point-of-need analysis approach has the 
potential to fulfil the World Health Organization (WHO) ASSURED criteria for an ideal 
rapid test: Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-
free, Deliverable to end-user.53  
Here, we investigate derivatization of DOX and OXY with diazotized 4-
aminoacetophenone (DAAP) to develop simple to use color based analysis method. We 
have developed this colorimetric method for traditional UV/vis spectroscopy and then 
adapted it for use on a paper-based platform to work towards a system that is accessible 
and affordable for routine analyses of pharmaceuticals. 
 
Experimental 
Apparatus and reagents 
A Shimadzu double beam recording spectrophotometer (UV–VIS 260 digital) was 
employed for absorbance measurements and the recording of spectra. All chemicals used 
were of analytical reagent grade. Distilled water was used for the preparation of all 
aqueous solutions. Pure doxycycline hyclate (DOX) and oxymetazoline hydrochloride 
(OXY) samples were kindly provided by the State Company for Drug Industries and 
Medical Appliance (SDI) (Samarra, Iraq). The formulated drugs were obtained from a local 
pharmacy in Baghdad (Iraq) as Doxycycline® 100 mg tablets (Gerot Lannach, Austria) and 
as Oxymetazoline® 0.1 % (1 mg mL-1) nasal drops from (Otrivin, GSK). 
 
Preparation of solutions 
Stock solutions of doxycycline hyclate (DOX) and oxymetazoline hydrochloride (OXY) (500 
mg L-1) were prepared by dissolving 0.05 g of each pure drug in 100 mL distilled water. 
Working standard solutions were prepared by suitable dilution of the stock standard 
solution with distilled water. 2 M NaOH was prepared by dissolving 20 g of NaOH (Merck) 
in 250 mL distilled water, and working solutions were prepared by appropriate dilution 
with the same solvent. Diazotized 4-aminoacetophenone (DAAP) solution (5×10-3 M) was 
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prepared daily by dissolving 0.0675 g of 4-aminoacetophenone (Merck) in 5 mL ethanol, 
20 mL distilled water and 2 mL of 0.8 M hydrochloric acid (Merck, 37% w/v) in a 100 mL 
volumetric flask. The mixture was cooled to 0-5 °C for 5 min using an ice-bath. Then 
0.0345 g of sodium nitrite (Fluka) was added and the mixture was stirred. After 5 min, the 
volume was made up to the mark with the addition of cooled distilled water.  
 
Analysis of commercial dosage forms 
DOX-containing powder tablets (100 mg DOX per tablet) were dissolved in distilled water 
and made up in a 100 mL volumetric flask and filtered to yield a 500 mg L-1 solution. This 
stock solution was diluted as required with distilled water. For OXY, a solution of 500 mg 
L-1 was prepared by diluting the over the counter drug with distilled water and diluted as 
required with distilled water. 
 
Spectrophotometric detection of DOX and OXY  
Into a series of 10 mL volumetric flasks, an increasing volume of DOX and OXY working 
solutions were transferred to cover the range of calibration concentrations. Then 1 mL of 
DAAP (5 mM) and 0.5 mL of NaOH (0.2 M) was added. The solutions were diluted to the 
mark with distilled water, mixed and then left for 10 min at room temperature (25 °C) to 
allow the color to develop.  The absorbance was measured at 425 nm and 521 nm for DOX 
and OXY, respectively, relative to the reagent blanks prepared in the same way containing 
no drugs. Calibration graphs were produced and regression equations were calculated. 
For the optimization of conditions and in all subsequent experiments were carried out on 
15 mg L-1 of DOX and OXY. Three repeats were carried out for each optimization and 
calibration experiment, this was achieved by taking three readings for each individual set 
of conditions investigated. Error bars were calculated using the standard deviation of the 






Colorimetric detection on μPAD platform 
Paper device fabrication The devices were designed using AutoCAD 2016 software and 
printed onto Whatman Grade 1 filter paper using a Xerox ColorQube 8570 wax printer 
with  ColorQube wax inks as described by Carrilho et al. 54 Adapting a method from 
Peters et al.55, the wax printed sheets were passed through a laminator (Fellows, model 
Callisto A4) three times at 125 °C. This allowed the wax to melt and flow through the 
porous paper to form a hydrophobic barrier throughout the entire paper thickness. The 
design featured eight circles, 10 mm diameter and 8 mm center to center distance, 
printed with 0.7 mm line width in green wax.  Each device also included a set of six colored 
squares as internal standard to account for changes in lighting conditions and camera to 
camera differences during image analysis.  
Assay measurements The microfluidic paper device featured a total of eight circular 
reaction zones of 10 mm diameter, thus allowing for eight separate measurements on the 
same device. The DOX assay was carried out by spotting 5 μL of the drug standard 
solutions, separately into seven of the eight reaction zones on the paper device using a 
micropipette. One reaction zone was left blank. Next, 5 μL of the reagent DAAP (5 mM) 
and 5 µL of NaOH (0.2 M) were pipetted into the seven reaction zones. Similarly, for the 
OXY assay, 5 µL of drug solution was pipetted onto the paper, followed by 5 µL of base 
and 5 µL of DAAP reagent. After pipetting, the paper devices were left to dry before a 
photograph was taken using a Samsung note 9 camera phone. Devices used for DOX 
investigation were photographed 20 min after the sample was added and for OXY after 
30 min.  The same procedure was also applied for the pharmaceutical samples. Each 
individual optimization and calibration experiment was repeated either 3 or 4 times detail 
shown in the figure caption, error bars were produced using the standard deviations of 




Image analysis Images were analyzed with ImageJ freeware56 (National Institutes of 
Health, USA, https://imagej.nih.gov/ij/docs/faqs.html) (figure S1). Akin to a method published 
by Boehle et al.,57 the .jpg images were first inverted. The image was then split into the 
three separate color channels (RED, GREEN and BLUE), for DOX reaction the BLUE channel 
was used and for OXY reaction the GREEN channel was used, as this was found to give the 
largest difference for measurements of varying sample concentrations. The area enclosed 
by the green wax barrier was analyzed by measuring the mean grey pixel intensity to give 
an average pixel intensity for each circle. To minimize effects from variations in 
environmental conditions an internal colored square was included in the PAD design. 
Average relative intensity (ARI) was obtained by dividing the average pixel intensity (AI) 
for the individual circles by the average pixel intensity of the yellow (DOX) or pink (OXY) 





Results and discussion 
DOX and OXY measurements via spectrophotometric analysis  
The coupling reaction between DAAP and DOX and OXY leading to the formation of the 
colored products is shown in Figure 1. Experimentally, yellow and red azo dyes were 
formed immediately after the addition of dilute aqueous solution of DOX and OXY to 
DAAP solution in alkaline conditions (around pH 12). These remained stable for at least 2 
h. The yellow and red products were found to have absorbance maxima at 425 nm for 
DOX and at 521 nm for OXY (Figure S2). 
 
For optimization of the dye-formation reaction, a 15 mg L-1 solution of DOX and/or OXY 
was employed and absorbance was measured relative to reagents blank at 425 nm and 
521 nm, respectively. Preliminary results indicated that the reaction was pH dependent, 
requiring basic conditions to develop a more intense yellow and red color. At basic pH, 
DOX and OXY form phenoxide anions, and these can readily react with DAAP to form the 
azo-dye. A range of alkaline solutions (0.2 M), namely sodium hydroxide, ammonium 
hydroxide and sodium carbonate, were investigated. The results, shown in figure S3, 
clearly indicated that sodium hydroxide was the most suitable reagent giving the 








Figure 1: Two step reaction pathway for the formation of azo-dye products, showing 4-
aminoacetophenone (DAAP) reacting with sodium nitrite under acidic conditions to form a 




The azo-dye formation for the DOX reaction was further optimized as summarized in 
Figure 2. Different volumes (0.25 mL to 3 mL) of sodium hydroxide (0.2 M) were compared 
(Figure 2a) whilst the other parameters were fixed. It was found that 0.5 mL gave the 
strongest color development. Next, the volume of DAAP reagent (5 mM) was varied 
between 0.5 mL and 3.0 mL (Figure 2b), and absorbance was found to increase with DAAP 
volume. Different orders of mixing the drug (D), NaOH base (B) and DAAP reagent (R) 
were also examined (Figure 2c). All combinations yielded a similar amount of product, 
and for future experiments, drug was applied, followed by reagent and base. Finally, the 
optimum reaction time to readout was investigated (Figure 2d). The colored reaction 
products were visible immediately, but the color intensity increased over time and 
reached a plateau at around 5 min, which was therefore chosen as the best suited 
development time. The colored product was found to be stable for at least 90 min in 
solution, however a fast readout time is desirable to shorten the workflow. 
 
The same optimization was carried also out for the OXY reaction (Figure 3). The best 
volume of NaOH was again found to be 0.5 mL. The volume of DAAP reagent (5 mM) was 
varied in the range of 0.5 mL to 2.5 mL, and 1.0 mL chosen as it gave a high color intensity. 
The mixing order of OXY followed by based and then DAAP reagent was chosen for future 
experiments. 
 
After optimization of the different parameters, calibration curves were obtained over the 
range 0.5 – 35 mg L-1 for DOX and 1 - 40 mg L-1 for OXY, respectively (Figure 4). The 
respective limits of detection and limits of quantification were found to be 0.244 mg L-1 








Figure 2: Optimization of reagent parameters for detection of DOX via the formation of a yellow 
azo-dye complex, all optimization experiments were carried out using 15 mg L-1 DOX solution. (a) 
The pH of the prepared solutions was increased by varying NaOH (0.2 M) between 0.25 mL and 3 
mL, n = 3, RSD ≤ 3%, (b) volume DAAP (5 mM) varied between 0.5 mL and 3.0 mL, n = 3, RSD ≤ 3%. 
(c) Optimization of reagent addition order, where D = DOX (15 mg L-1), R = DAAP (5 mM), B = NaOH 
(0.2 M), n = 3, RSD ≤ 4%. (d) Development of yellow azo-dye product over time, absorbance 
recorded between 1 min and 20 min, showing rapid development of color up to 5 min, then 




Figure 3: Optimization of reagent parameters for detection of OXY via the formation of a red 
azo dye complex, all optimization experiments were carried out using 15 mg L-1 OXY solution. (a) 
The pH of the prepared solutions was increased by varying NaOH (0.2 M) between 0.25 mL and 3 
mL, n = 3, RSD ≤ 3%. (b) volume DAAP (5 mM) varied between 0.5 mL and 3.0 mL, n = 3, RSD ≤ 3%.   
(c) Optimization or reagent addition order were D = DOX (15 mg L-1), R = DAAP (5 mM), B = NaOH 
(0.2 M), n = 3, RSD ≤ 3%. (d) Development of red azo-dye product over time, absorbance recorded 
between 1 min and 20 min showing rapid development of color up to 5 min, then reaching a 
plateau with no further development of color occurring, n = 3, RSD ≤ 1%. 
 
Figure 4: Linear calibration obtained for (a) DOX (0.5 - 35 mg L-1) and (b) OXY (1 - 40 mg L-1), n = 
3, RSD ≤ 3 %.  
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DOX and OXY measurements via μPADs  
 
The paper microfluidic platform was investigated as an alternative to the conventional 
laboratory-base spectrophotometer method. The porous matrix of the paper cellulose 
fibers potentially allows for the storage of reagents, which, when added sequentially 
would mix to form the azo dye complexes, i.e. a yellow colored complex for DOX and a 
red colored complex for OXY. This was achieved by adding aqueous reagents to cellulose 
filter paper that had been patterned with wax to create circular reaction zones within the 





Figure 5: Adaptation of traditional bench top chemistry to paper-based platform. (a) Reaction 
of DOX (0 and 40 mg L-1) with DAAP in alkaline conditions to produce yellow azo-dye.                            
(b) Reaction of DOX (0 and 35 mg L-1) with DAAP in alkaline conditions to produce red azo-dye. (c) 
Reaction performed on paper microfluidic device with reagents and analyte added to the circular 







Initial studies were performed to optimize the various parameters with a view to establish 
the maximum color intensity on the paper devices. The influence of varying the volume 
of the spotted reagents was studied. Insufficient reagent volumes may cause a decrease 
in intensity, while the excess of addition may lead to reagent leaking out of the sensing 
zone. The results for the DOX reaction are shown in Figure 6. The NaOH (0.2 M) volume 
was varied between 3 µL and 9 µL, as shown in Figure 6a. At 5 µL, a fairly uniform color 
distribution of high intensity was observed. The volume of DAAP reagent was also varied 
in the range of 3 µL to 9 µL and the color intensity was found to decrease somewhat with 
an increasing volume of DAAP (Figure 6b). The volume of 5 µL was chosen, as it was 
sufficient to develop even color across the reaction zone without overloading the zone, 
potentially leading to leakage over the barrier. Next, the addition order of each reagent 
was studied, similar to previous experiments. For the reaction with DOX the addition 
order influenced the final result. Figure 6c clearly shows the importance of adding the 
DOX solution followed by DAAP and then the base to obtain the greatest sensitivity. 
 
Finally, the reaction time required to obtain maximum and stable intensity was 
investigated. Previous experiments had shown the reaction progresses quickly in solution 
reaching a stable color by 5 min. On the paper device, the formed product was measured 
over the period from 0 to 60 min. As shown in Figure 6d, the product formation initially 
increased, with 20 min chosen as best suited development time for the DOX reaction. 
However, unlike in the solution based methods, the color intensity was found to decrease 
beyond 40 min, indicating that the product was not stable.  
 
 
Similarly, the OXY reaction on paper was optimized (Figure 7) and again 5 µL was found 
to be a suitable volume for NaOH. The DAAP volume did not influence the color intensity 
significantly, suggesting that the reaction was not limited by DAAP volume under the 
conditions used therefore 5 µL was again chosen as it allowed development of an even 
color across the reaction zone without leakage over the barrier. For the reaction with OXY 
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the reagent order addition was not important and had little impact on the final result, as 
was also seen with the spectroscopic method. The development time of 30 min was 






Figure 6: Optimization of reaction parameters for detection of DOX via the formation of a yellow 
azo-dye on the paper device, all optimization experiments were carried out using 15 mg L-1 DOX 
solution, n = 3. (a) Volume of NaOH (0.2 M) varied between 3 µL and 9 µL. (b) Volume of DAAP 
reagent (5 mM) varied between 3 µL and 9 µL. (c) Effect of order of reagent addition order with D 
= DOX (15 mg L-1), R = DAAP (5 mM) and B = NaOH (0.2 M). (d) Development of yellow azo-dye 




Figure 7: Optimization of reaction parameters for detection of OXY via the formation of a 
reddish-pink azo-dye on the paper device, all optimization experiments were carried out using 15 
mg L-1 OXY solution, n = 3. (a) Volume of NaOH (0.2 M) varied between 3 µL and 9 µL. (b) Volume 
of DAAP reagent (5 mM) varied between 3 µL and 9 µL. (c) Study of reagent addition order, where 
D = DOX (15 mg L-1), R = DAAP (5 mM) and B = NaOH (0.2 M). (d) Development of reddish-pink azo-
dye product over time, absorbance recorded between 0 and 60 min. 
 
Following optimization of the reaction parameters, calibration curves were obtained for 
DOX (0.5 – 35 mg L-1) and OXY (1 – 40 mg L-1) using 5 µL of DAAP (5 mM) and NaOH (0.2 
M) as shown in Figure 8. Images were captured 20 and 30 min after addition for DOX and 
OXY, respectively. For both, there was a linear increase in color intensity from drug 
concentration exceeding 15 mg L-1. At lower concentrations, color intensity was fairly 






Figure 8: Calibration data showing a linear trend above 15 mg L-1 for (a) DOX (0.5 - 35 mg L-1) and 
(b) OXY (1 - 40 mg L-1), n = 4. 
 
 
Analysis of pharmaceutical dosage forms 
To assess the efficiency of the method and investigate potential interference from the 
sample matrix of the tablets and nasal drops solution additives, DOX and OXY 
concentrations within two pharmaceutical products were determined. The products 
tested were Doxycycline for DOX and Otrivin for OXY, as detailed in the experimental 
section. The formulations were prepared in two different concentrations and absorbance 
compared to the calibration curves.  The results are summarized in Table 1. Rec.% refers 
to the amount of DOX or OXY found in the prepared solution, when analyzed by UV/vis 
absorption compared to the amount that should be detected, i.e. the stated 
concentration in the preparation. RSD% indicates the relative standard deviation of the 
four repeats. With RSD% £2.2% and Rec.% within £2.2% to the expected value, the 





Table 1: Analysis via UV/vis absorption of Doxycycline® tablets and Oxymetazoline® Nasal drops 









(mg L-1), n = 4 
Rec.% RSD% 
Doxycycline® tablets 
5.00 4.89 97.80 2.04 
10.0 10.02 100.20 1.10 
Oxymetazoline®  
Nasal drops 
5.00 5.06 101.20 2.11 
10.0 9.89 98.90 1.66 
 
 
In comparison to UV/vis detection, the paper devices were suitable for semi-quantitative 
analysis, a linear trend for both was seen above 15 mg L-1. To investigate this with real 
samples, a 15 mg L-1 solution of DOX and OXY was prepared for the pharmaceutical 
formulations and compared to a blank sample (figure 9). Both drugs at 15 mg L-1 show a 




Figure 9: Comparison of a real sample (15 mg L-1 DOX tablets and 15 mg L-1 OXY from nasal spray 
with a blank (reagents only). For OXY the positive control and blank were significantly different at 
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p = 0.001, showing equal variance between the two with F < Fcrit (1.5 < 141.1) and 2 tailed t test, 
assuming equal variance showed significant difference between the two values, tstat > tcrit two-tailed 
(13.1 > 6.0). For DOX the two were significantly different at p = 0.05, showing unequal variance 
between the two with F > Fcrit (6.8 > 9.3) and 2 tailed t test, assuming equal variance showed 








We have employed a diazotization reaction for quantitative measurement of DOX and 
OXY using absorption spectrophotometry. Future work would include widening of types 
of drugs to be analyzed and a study on the stability of the reaction products, the potential 
of prestoring the reagents and studying reagent stability over an extended period of time. 
The paper-based testing device provides an inexpensive, simple and easy-to-use 
alternative that can be performed outside centralized laboratories with semi-quantitative 
capability.  
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